This session will include three presentations focused on current work using ‘omics to inform cardiovascular and renal pathophysiology, which are highly correlated in SCD. Further, these outcomes are associated with risk for early mortality and therefore are of significant import to patient quality of life and survival. Dr. Gladwin will discuss the use of multiple omics to understand hemolytic anemia and transfusion medicine as they relate to cardiopulmonary outcomes in SCD. Dr. Ashley-Koch will discuss recent application of multiple omics to dissect risk for sickle nephropathy. Finally, Dr. Nekhai will discuss the use of urinary proteomics to understand sickle nephropathy.